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Abstract
Background: Advanced pancreatic cancer (PC) has very poor prognosis with present treatments, thus necessitating
continued efforts to find improved therapeutic approaches. Both preclinical and preliminary clinical data indicate
that cytokine-induced killer (CIK) cells are an effective tool against various types of solid tumors. Here, we
conducted a study to determine whether CIK cell-based therapy (CBT) can improve the outcomes of advanced PC.
Methods: Eighty-two patients with advanced PC, whose predicted survival time was longer than 3 months, were
analyzed retrospectively. Of all the patients, 57 individuals were receiving chemotherapy, while the remaining 25
individuals were treated with CBT.
Results: The overall survival analysis was based on 48 deaths in the 57 patients in the chemotherapy group
(84.2 %) and 18 deaths in the 25 patients in the CBT group (72.0 %). In the CBT group, the median overall survival
time was 13.5 months, as compared to 6.6 months in the chemotherapy group (hazard ratio for death, 0.39; 95 %
confidence interval, 0.23 to 0.65; p < 0.001). The survival rate was 88.9 % in the CBT group versus 54.2 % in the
chemotherapy group at 6 months, 61.1 % versus 12.5 % at 12 months, and 38.9 % versus 4.2 % at 18 months. The
disease control rate was 68.0 % in the CBT group and 29.8 % in the chemotherapy group (p < 0.001).
Conclusions: These results from this retrospective analysis appeared to imply that CBT might prolong survival in
these high-risk PC patients. Prospective study is needed to corroborate this observation.
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Background
Pancreatic cancer (PC) has the poorest prognosis among
all gastrointestinal cancers, with 1-year survival rate of
around 20 % and 5-year survival rate of 7 % for diagnosed
patients [1–3]. Gemcitabine is a chemical agent used as
standard chemotherapy treatment for advanced PC. How-
ever, patients treated with this agent alone have a median
overall survival time (mOS) of no more than 8.3 months,
and the results of most clinical trials show that the mOS
of advanced PC patients is not significantly prolonged
when gemcitabine is combined with other cytotoxic or tar-
geted agents [3–5]. Patients who received FOLFIRINOX
(oxaliplatin, irinotecan, fluorouracil, and leucovorin) or
nab-paclitaxel combined with gemcitabine therapy show
an improvement in mOS, with an increase of 4.3 or
1.8 months, respectively [2, 6]. However, these strategies
are associated with a higher incidence of serious side ef-
fects, and the patients must therefore undergo rigorous
testing prior to chemotherapy to have evaluated suitability
for therapy, and further require close monitoring during
the therapy. Thus, new therapeutic strategies for advanced
PC treatment are urgently needed.
A promising approach treating PC is the use of im-
mune checkpoint inhibitors. The targets of these treat-
ments are the molecules that serve as checks in the
regulation of immune responses. By blocking inhibitory
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molecules, these treatments will activate the immune
system and as such reactivate preexisting anti-cancer re-
sponses [7–11]. Several checkpoint inhibitors are cur-
rently in development.
Another major avenue of immunotherapy for PC is
adoptive T cell transfer. Cytokine-induced killer (CIK)
cells are a heterogeneous subset of T lymphocytes ex-
panded ex vivo that express CD3 and CD56 as well as
natural killer group 2, member D molecules (NKG2D).
Adoptive transfer of CIK cells has been shown to be ef-
fective for cancer treatment, with high safety, as indi-
cated by the prolonged survival of patients with different
types of tumors [12–17]. When used in combination
with chemotherapy, CIK cells show enhanced efficacy in
preventing disease recurrence and improving the prog-
nosis of cancer patients [18–20]. Recently, researchers
have been taking advantage of CIK cells as a second-line
treatment to treat advanced PC, and the results obtained
showed encouraging results, both in terms of single use
and combined use with other treatments. For example,
in a phase 2 clinical trial, patients with CIK cells in
gemcitabine-refractory advanced PC displayed a mOS of
6.2 months [21]. Another clinical study showed that pa-
tients who received CIK cells in combination with S-1,
an oral fluoropyrimidine derivative, in gemcitabine-
refractory advanced PC displayed a mOS of 6.6 months,
which is longer than mOS of patients receiving S-1
alone (6.1 months) [22]. However, data are lacking on
the efficacy of CIK cells as a first-line treatment in pa-
tients with advanced PC.
In this study, we performed a retrospective study,
where we compared the mOS of patients with advanced
PC, who have been treated with CBT or chemotherapy
as a first-line treatment.
Results
Characteristics of the patients
A total number of 82 patients were enrolled in this study.
Of these, 57 patients received chemotherapy alone, and 25
patients received CBT. The last follow-up examination of
the patients was performed on September 13, 2014.
Although sample numbers were different in the two
groups, the baseline demographic and clinical characteris-
tics of patients were relatively well balanced (Table 1 and
Additional files 1 and 2).
Survival
The overall survival analysis was based on 48 deaths in
the 57 patients in the chemotherapy group (84.2 %) and
18 deaths in the 25 patients in the CBT group (72.0 %).
The mOS was 13.5 months in the CBT, as compared
with 6.6 months in the chemotherapy group (hazard ra-
tio for death, 0.39; 95 % CI, 0.23 to 0.65; p < 0.001)
(Fig. 1). The overall survival rates at 6, 12, and 18 months
were 88.9, 61.1, and 38.9 %, respectively, in the CBT
group, as compared with the survival rate of 54.2, 12.5,
and 4.2 % in the chemotherapy group.
Response
Of 57 patients in the chemotherapy group, no complete
responses were seen, 3 patients exhibited a partial re-
sponse (5.3 %), 14 patients displayed stable disease
(24.6 %), and 40 patients showed progressive disease
(70.2 %) (Fig. 2a). Of 25 patients in the CBT group, 1
complete response was seen (4.0 %), 2 patients exhibited
a partial response (8.0 %), 14 patients displayed stable
disease (56.0 %), and 8 patients showed progressive dis-
ease (32.0 %) (Fig. 2b). The DCR rate was 29.8 % (17/57)
in the chemotherapy group and 68.0 % (17/25) in the
CBT group. The DCR rate was significantly higher in the
CBT group than in the chemotherapy group. (p < 0.001,
Fig. 3).
Adverse events
The major adverse events are listed in Table 2. Patients in
the CBT group seemed to have higher incidences of fever
and fatigue as compared with patients in the chemother-
apy group. The difference was minimal, statistically not
significant, and was considered to be attributed to the
most common side effect of IL-2 administrated after CIK
cell transfusion [14]. There were no significant differences
in leucopenia, neutropenia, thrombocytopenia, nausea,
diarrhea, vomiting, and infection between the two groups.
Discussion
Overall survival time has traditionally been regarded as
the most reliable endpoint in evaluating an experimental
strategy for cancer treatment, and thus its improvement
is an important criterion for regulatory approval of a
new therapy. However, most large-scale clinical phase 3
studies have not shown significantly improved survival
in advanced PC. Our data presented here suggest that in
patients with advanced PC, the overall survival was signifi-
cantly improved when the patients were treated with CBT,
relative to patients who received chemotherapy alone.
More importantly, CIK cell-associated toxicity was mild,
with fever as the main side effect, at an incidence rate of
approximately 15 % [14]. This suggests that CIK cell treat-
ment has a higher efficacy and safety in advanced PC.
Gemcitabine and fluorouracil are two widely used che-
motherapeutical agents in advanced PC. Previous studies
have shown that gemcitabine suppresses the production
of IgG antibody but does not affect the specific anti-
tumor immunity [23, 24]. In another study, it was shown
that the anti-tumor effect of gemcitabine does not result
from direct cytotoxic effects on tumor cells but rather
from an enhancement of T cell-mediated immune re-
sponses [25]. These data suggest that gemcitabine acts
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as an immunomodulator, making it a good candidate
drug for combination with immunotherapy strategies.
This notion is supported by two experimental studies
showing that combination of a dendritic cell vaccine
with gemcitabine improved the survival of tumor-
bearing hosts in a murine pancreatic carcinoma model
[26, 27]. Fluorouracil also exhibited immunomodulatory
effects when combined with immunotherapy strategies
[28]. Thus, the immunomodulatory effects of gemcita-
bine and fluorouracil play an important role for hosts to
elicit robust anti-tumor immunity. On the basis of these
data and our results, we propose that when combined
with immunomodulatory chemotherapeutical agents,
CIK cells exhibit even higher, more potent anti-tumor
activity.
Previous in vitro experiments show that cultured CIK
cells possess significant cytotoxic activity against tumor
cells and most of the cytotoxicity is attributed to the
higher proliferation of CD3+CD56+ cells [29, 30]. In vivo,
CIK cells can migrate to the site of tumors through
interacting with chemokine receptors expressed on the
surface of them, where they release their cytotoxic
Table 1 Demographic and clinicopathological characteristics of the patients at baseline
Characteristics Chemotherapy (n = 57) CBT (n = 25) p value
Number % Number %
Sex
Male 35 61.40 15 60.00 1.00
Female 22 38.60 10 40.00
Age, years
<65 38 66.67 14 56.00 0.46
≥65 19 33.33 11 44.00
Diagnosis basis
Pathologically 29 50.88 14 56.00 0.81
Clinically 28 49.12 11 44.00
Extent of disease
Locally advanced 9 15.79 2 8.00 0.49
Metastatic 48 84.21 23 92.00
Measurable metastatic sites
Livera 30 52.63 13 52.00 1.00
Other 27 47.37 12 48.00
No. of metastatic sites
1 32 56.14 16 64.00 0.83
2 18 31.58 7 28.88
≥3 7 12.28 2 8.00
ECOG performance status score
1 20 35.09 9 36.00 1.00
2 37 64.91 16 64.00
Pancreatic tumor location
Head 21 36.84 14 56.00 0.17
Body 5 8.78 4 16.00
Tail 16 28.07 3 12.00
Multicentricb 15 26.32 4 16.00
Level of carbohydrate antigen 19-9 - u/ml
Abnormal 47 82.46 20 80.00 0.23
Normal 6 10.53 5 20.00
Unknownc 4 7.02 0 0.00
aPatients with liver-only metastasis or liver-containing metastases were included
bWhen tumor infiltrated more than one region of pancreas, it was defined as multicentric. It included head-body, head-tail, body-tail, and head-body-tail tumors
cFour patients did not carry out this detection for economic condition
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potential and inhibit tumor growth [31–33]. The mo-
lecular mechanisms of tumor recognition and killing by
CIK cells possibly involve the expression of lymphocyte
function-associated antigens, NKG2D, DNAS accessory
molecule-1, and NKp30 [29, 34]. Besides their direct
cytotoxic effect, CIK cells secret interferon gamma that
modulates the expression of adhesion molecules on
tumor cells, and the altered expression pattern of adhe-
sion molecule enhances apoptosis that is induced by
cytotoxic effector cells [35]. In addition, recent studies
report that CIK cells attack cancer stem cells in both
animal models and human patients [13, 33]. Finally, pre-
vious work using a mouse model indicates that cancer
immunotherapy using interferon alpha can significantly
reduce chemotherapy-induced expression of multi-drug
resistance proteins, as well as lower the activity of drug
efflux out of the cancer cells subjected to this treatment,
thus rescuing their chemosensitivity [36]. This result
suggests that CIK cells increase the sensitivity of PC cells
to gemcitabine and/or S-1, which is another possible
mechanism for CIK cell anti-tumor action.
Recently, Arina and colleagues suggest that the pres-
ence of myeloid-derived suppressor cells (MDSC) limits
adoptively transferred T cell infiltration and function,
and manipulation of intratumoral myeloid cells may im-
prove the outcome of otherwise unsuccessful adoptive
transferred T cells [37]. Both gemcitabine and fluoroura-
cil were known to be selectively cytotoxic on MDSC
whereas no significant effect on T cells in animal models
[38, 39], and MDSC decrease was observed when these
chemotherapeutic agents were used in cancer patients
[40, 41]. Thus, it is reasonable that CIK cells combined
with these agents led to a better effect in advanced PC
patients.
Our survival analysis has several major experimental
limitations. First of all, this is a retrospective, non-
randomized study, and only patients from medical wards
of our hospital were included, which may not truly re-
flect patients from other hospitals. Moreover, survival
differences between CBT and chemotherapy might be af-
fected by differences during patient selection and differ-
ences in standard and supportive care treatment. A
second limitation of our analysis is that we did not have
Fig. 2 Waterfall chart demonstrating changes in tumor measurement
with measurable tumor at baseline. Response to therapy was
calculated in 57 patients with chemotherapy (a) compared with
25 patients with CBT (b)
Fig. 1 Overall survival time for CBT versus chemotherapy alone
in patients with advanced PC. Overall survival was calculated in 18
patients with CBT compared with 48 patients with chemotherapy
Fig. 3 Comparison of the DCR rate in the CBT group and
chemotherapy group
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detailed information on the post-chemotherapy treat-
ment in the chemotherapy group, and this could con-
tribute to the difference in mOS between the two
groups. Thirdly, the use of chemotherapeutic agents in
the two groups was not standardized. Despite this differ-
ence in chemical agents between the two groups, we be-
lieve that such difference had no significant influence on
the difference in mOS, since the results of previous clin-
ical trials clearly indicated that there was no significant
increase in mOS when two or more drugs were com-
bined. Thus, the observed therapeutic benefits in the
combined group were considered to be a result of the
transfusion with CIK cells.
Conclusions
In summary, the fact that we observed prolonged survival
for patients receiving CBT supports the notion that CIK
cells can greatly improve the prognosis of advanced PC.
Based on the data presented here, other estimates of clinical
benefit such as objective response rate and progression-free
survival and improved quality of life, CBT will hopefully be-
come a standard of care for patients with advanced PC.
Methods
Patient selection
Patients in this retrospective analysis were admitted be-
tween 1 September 2010 and 4 May 2014 in Henan Can-
cer Hospital. The criteria for patients included in the
study were the following: (1) PC was histologically or
cytologically confirmed (pathologically diagnosed), or di-
agnosed by symptoms and complications, computer
tomography or magnetic resonance imaging, combined
with measurement of serum carbohydrate antigen 199
levels (clinically diagnosed). (2) The ECOG performance
status was below 3. (3) The predicted survival time was
longer than 3 months. (4) Age is larger than 18 years. (5)
Uncontrolled infection was absent. Unresectability was
assessed by an experienced surgeon either during laparot-
omy or by radiologic work-up (computed tomography
scan and/or magnetic resonance imaging) showing portal
and/or mesenteric and/or celiac vascular involvement.
Any extrapancreatic disease including Vater’s ampulloma
and adenocarcinoma of the biliary tract was an exclusion
criterion. We listed all patients who met the above criteria
and surveyed their records. All patients gave written in-
formed consent, which had been approved by the institu-
tional review board of Zhengzhou University. This study
was conducted in accordance with the provisions of the
Declaration of Helsinki and Good Clinical Practice
guidelines.
Study design
CIK cells were prepared according to the procedures de-
scribed in a previous study [13]. Briefly, peripheral blood
mononuclear cell were separated and cultured under ster-
ile conditions with 1640 medium containing anti-CD3
monoclonal antibody, interferon gamma, interleukin-2,
and RetroNectin (RN, Takara, Japan). After culturing of
cells for 10 to 14 days, a target dose of about 5 × 109 CIK
cells with over 95 % viability was obtained and tested for
biological contaminants. The modified method led to a
significant higher proportion of CD3+CD56+ cellular sub-
set [14]. Anti-tumor cytokines such as tumor necrosis fac-
tor alpha were higher and pro-tumor cytokines such as
interleukin-4 and interleukin-5 were lower in the CIK cell
cultures prepared with the modified method (data not
shown). Cells were then prepared in 2 % albumin contain-
ing sodium chloride solution before transfusion into the
patients. In the following 3 days, patients were adminis-
tered with interleukin-2 (2 million IU per day) to promote
CIK activity. Patients in this study received at least 2 cycles
of CIK cell transfusion.
In the CBT group, 21 patients received CIK cell trans-
fusion plus gemcitabine (1000 mg/m2, d1, 8) and/or S-1
(orally twice daily at a dose according to the body sur-
face area (<1.25 m2, 80 mg/day; 1.25–1.5 m2, 100 mg/day;
>1.5 m2, 120 mg/day) on days 1–14), one patient received
CIK cell transfusion plus epotoside (60 mg/m2, d1-5), and
three cases received only CIK cells. Transfusion of CIK cells
was followed at the end of each cycle of chemotherapy. Pa-
tients received chemotherapy every 3-week period.
In the chemotherapy group, 54 patients received gemci-
tabine (1000 mg/m2, d1, 8) and/or S-1-based (orally twice
daily at a dose according to the body surface area
Table 2 Adverse events (AEs) among patients in chemotherapy and CBT groups
Adverse event Chemotherapy (n = 57) CBT (n = 25) p value
Number % Number %
Myelosuppressiona 33 57.89 10 40.00 0.16
Digestive tract symptomb 18 31.58 5 20.00 0.42
Fever 2 3.51 3 12.00 0.16
Fatigue 2 3.51 2 8.00 0.58
Infection 2 3.51 0 0 1.00
aMyelosuppression includes thrombocytopenia, lymphopenia, and neutropenia
bDigestive tract symptom includes nausea, vomiting, and diarrhea
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(<1.25 m2, 80 mg/day; 1.25–1.5 m2, 100 mg/day; >1.5 m2,
120 mg/day) on days 1–14) chemotherapy, one patient re-
ceived epotoside (60 mg/m2, d1-5) and cisplatin (15 mg/
m2, d2-5), one patient received nab-paclitaxel (110 mg/
m2, d1, 8) and gemcitabine (1000 mg/m2, d1, 8), and one
patient received an intraperitoneal perfusion of cisplatin
(20 mg/m2, d1, 2). Patients received chemotherapy every
3-week period.
Evaluation of short-term efficacy and toxicity
The tumor response was assessed according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST):
complete response (CR), partial response (PR), stable dis-
ease (SD), and progressive disease (PD). We performed
tumor assessments with the use of computed tomographic
(CT) scanning at baseline and 2 months post treatment
start. Efficacy was evaluated by disease control rate (DCR),
consisting of CR, PR, and SD. Safety was assessed by
documentation of adverse events. Hematologic and serum
chemical measurement were performed before and after
each cycle of treatment. Adverse events were graded with
the use of the Common Terminology Criteria for Adverse
Events of the National Cancer Institute, version 3.0.
Statistical analysis
Fisher’s exact test or chi-square test were used to assess
the association of the treatment group with demographic
and clinicopathological characteristics as well as the re-
sponse to therapy. Overall survival was estimated using
the Kaplan-Meier method, and the log-rank test was
used to compare the difference between the two groups.
The hazard ratio between the two groups was estimated
by proportional hazards regression using a 95 % Wald
confidence interval (95 % CI). Data analysis was done
with Graphpad Prism 5, with all p values applied as two-
sided.
Additional files
Additional file 1: Demographic and clinical characteristics of
individual patient in chemotherapy group. (DOC 85 kb)
Additional file 2: Demographic and clinical characteristics of
individual patient in CBT group. (DOC 43 kb)
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